Download PDF
Thromb Haemost 1984; 51(02): 189-191
DOI: 10.1055/s-0038-1661055
Original Article
Schattauer GmbH Stuttgart

Observations on the Heparin Neutralizing Activity of Outdated Platelet Concentrates

B L Griffiths
The Research and Development Laboratory, Canadian Red Cross Society, Blood Transfusion Service and the Blood Coagulation Laboratory, Health Sciences Centre, St. John’s, Newfoundland
,
J R Collins
The Research and Development Laboratory, Canadian Red Cross Society, Blood Transfusion Service and the Blood Coagulation Laboratory, Health Sciences Centre, St. John’s, Newfoundland
,
R G Huntsman
The Research and Development Laboratory, Canadian Red Cross Society, Blood Transfusion Service and the Blood Coagulation Laboratory, Health Sciences Centre, St. John’s, Newfoundland
› Author Affiliations
Further Information

Publication History

Received 27 March 1983

Accepted 09 January 1984

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A crude extract of outdated, washed, frozen and thawed, platelet concentrates was prepared and optimally diluted for use in the A. P. T. T. test as a source of platelet phospholipid (P. F. 3). The extract contained, in addition to P.F. 3, active heparin neutralizing activity (P. F. 4), which was able to neutralize plasma heparin up to a concentration of approximately 0.8 units/ml plasma. Although these observations are of a preliminary nature, it is felt that the extract can be used to follow the “intrinsic” coagulability of plasma samples from patients receiving therapeutic heparin. Utilizing the A. P. T. T. test system, the determination of coagulability and the neturalization of heparin result from the use of this extract in a single test.

Keywords

Platelet factor 4 - Heparin neutralizing activity - Activated partial thromboplastin time (A.P.T.T.)
 

  • References

  • 1 Conley CL, Hartmann RC, Lalley JS. The relationships of heparin activity to platelet concentration. Proc Soc Exp Biol Med 1948; 69: 284-286
    CrossrefPubMedGoogle Scholar
  • 2 Creveld vanS, Paulssen MM. Significance of clotting factors in blood platelets in normal and pathological conditions. Lancet 1951; 2: 242-244
    PubMedGoogle Scholar
  • 3 Jurgens R. Funktion der Thrombozyten bei Blutung und Thrombose. Wiener Klin Wachr 1954; 66: 8504
    PubMedGoogle Scholar
  • 4 Kubisz P, Levy-Toledano S, Cronberg S, Pinkhas J, Caen J. Effect of phentolamine, an alpha receptor blocking agent, on epinephrine, ADP and collagen induced platelet factor 4 release and platelet aggregation. Rev Eur Etud Clin Biol 1970; 15: 429-432
    PubMedGoogle Scholar
  • 5 Niewiarowski S, Lipinski B, Farbiszewski R, Poplawski A. The release of platelet factor 4 during platelet aggregation and the possible significance of this reaction in haemostasis. Experientia 1968; 24: 343-344
    CrossrefPubMedGoogle Scholar
  • 6 Donati MB, Palester-Chlebowczyk M, de Gaetano G, Verlen J. Platelet factor 4: properties and clinical significance. In: Platelet Function and Thrombosis. Mannucci PM, Gorini S. (eds) Plenum Press; New York: 1972. pp 173-189
    Google Scholar
  • 7 Yin ET, Wessler S, Butler J. Plasma heparin: a unique, practical submicrogram sensitive assay. J Lab Clin Med 1973; 81: 298-310
    PubMedGoogle Scholar
  • 8 Jacques LB, Walters ET. Identity and origin of anticoagulant of anaphylactic shock in dog. J Physiol 1941; 99: 454-466
    CrossrefPubMedGoogle Scholar
  • 9 Preston FW, Parker RP. New antiheparin agent: polybrene; effect in peptone shock and in experimental radiation injury. Arch Surg 1953; 66: 545-551
    CrossrefPubMedGoogle Scholar
  • 10 Hirsh J, Genton E, Hull R. Venous Thromboembolism. Grune and Stratton; New York: 1981. p 166
    Google Scholar